Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Non-Controlled Clinical Efficacy Study Following Brain Six Complex Extractⓒ Administration in Dogs with Cognitive Dysfunction Syndrome

  • Ga-Won Lee (Department of Companion Animal Industry, College of Health and Welfare, Dongshin University) ;
  • Woong-Bin Ro (Department of Veterinary Emergency and Critical Care Medicine, College of Veterinary Medicine, Chonnam National University) ;
  • Min-Hee Kang (Department of Bio-Animal Care, Jangan University) ;
  • Heyong-Seok Kim (Petobio, Inc.) ;
  • Hee-Myung Park (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
  • Received : 2023.09.05
  • Accepted : 2023.11.07
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The incidence of canine cognitive dysfunction syndrome (CCDS), a prominent geriatric disease, is increasing because of the extended lifespan of companion animals. Various complementary therapies have been proposed for the management of CCDS. This study evaluated the clinical efficacy of the Brain Six Complex Extractⓒ in dogs with cognitive dysfunction syndrome (CDS). Fifteen dogs with CDS were included, and four to five drops of Brain Six Complex Extractⓒ, composed of herbal extracts, were applied around the dorsal neck of all dogs twice daily for 1-3 months. Clinical efficacy was evaluated using the CCDS scale, and serum β-amyloid oligomer concentrations were measured before and after administration of the extract. The CCDS scale score significantly decreased after administration in dogs with CDS (p = 0.0313), compared to pre-administration levels. Although the serum β-amyloid oligomer concentration decreased after administration, the change was not statistically significant (p > 0.05). A notable decrease was observed between pre- and post-administration in dogs with β-amyloid levels >300 pg/mL (p = 0.0313). The laboratory results showed no remarkable adverse effects of the extract. This study suggests that Brain Six Complex Extractⓒ extract could be an adjunctive treatment for dogs with CDS.

Keywords

References

  1. Ball EL, Owen-Booth B, Gray A, Shenkin SD, Hewitt J, McCleery J. Aromatherapy for dementia. Cochrane Database Syst Rev 2020; 8: CD003150.
  2. Blennow K, Zetterberg H. Fluid biomarker-based molecular phenotyping of Alzheimer's disease patients in research and clinical settings. Prog Mol Biol Transl Sci 2019; 168: 3-23. https://doi.org/10.1016/bs.pmbts.2019.07.006
  3. Dewey CW, Davies ES, Xie H, Wakshlag JJ. Canine cognitive dysfunction: pathophysiology, diagnosis, and treatment. Vet Clin North Am Small Anim Pract 2019; 49: 477-499. https://doi.org/10.1016/j.cvsm.2019.01.013
  4. Ebihara T, Yamasaki M, Kozaki K, Ebihara S. Medical aromatherapy in geriatric syndrome. Geriatr Gerontol Int 2021; 21: 377-385. https://doi.org/10.1111/ggi.14157
  5. Fast R, Schutt T, Toft N, Moller A, Berendt M. An observational study with long-term follow-up of canine cognitive dysfunction: clinical characteristics, survival, and risk factors. J Vet Intern Med 2013; 27: 822-829. https://doi.org/10.1111/jvim.12109
  6. Huang YR, Liu RT. The Toxicity and polymorphism of β-amyloid oligomers. Int J Mol Sci 2020; 21: 4477.
  7. Kouzuki M, Kitao S, Kaju T, Urakami K. Evaluation of the effect of aroma oil as a bath salt on cognitive function. Psychogeriatrics 2020; 20: 163-171. https://doi.org/10.1111/psyg.12481
  8. Landsberg GM, Nichol J, Araujo JA. Cognitive dysfunction syndrome: a disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract 2012; 42: 749-768, vii. https://doi.org/10.1016/j.cvsm.2012.04.003
  9. Liu B, Kou J, Li F, Huo D, Xu J, Zhou X, et al. Lemon essential oil ameliorates age-associated cognitive dysfunction via modulating hippocampal synaptic density and inhibiting acetylcholinesterase. Aging (Albany NY) 2020; 12: 8622-8639. https://doi.org/10.18632/aging.103179
  10. Ozawa M, Chambers JK, Uchida K, Nakayama H. The relation between canine cognitive dysfunction and age-related brain lesions. J Vet Med Sci 2016; 78: 997-1006. https://doi.org/10.1292/jvms.15-0624
  11. Pan Y, Landsberg G, Mougeot I, Kelly S, Xu H, Bhatnagar S, et al. Efficacy of a therapeutic diet on dogs with signs of cognitive dysfunction syndrome (CDS): a prospective double blinded placebo controlled clinical study. Front Nutr 2018; 5: 127.
  12. Phochantachinda S, Chantong B, Reamtong O, Chatchaisak D. Change in the plasma proteome associated with canine cognitive dysfunction syndrome (CCDS) in Thailand. BMC Vet Res 2021; 17: 60.
  13. Pinheiro L, Faustino C. Therapeutic strategies targeting Amyloid-β in Alzheimer's disease. Curr Alzheimer Res 2019; 16: 418-452. https://doi.org/10.2174/1567205016666190321163438
  14. Stylianaki I, Polizopoulou ZS, Theodoridis A, Koutouzidou G, Baka R, Papaioannou NG. Amyloid-beta plasma and cerebrospinal fluid biomarkers in aged dogs with cognitive dysfunction syndrome. J Vet Intern Med 2020; 34: 1532-1540. https://doi.org/10.1111/jvim.15812
  15. Tolar M, Hey J, Power A, Abushakra S. Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci 2021; 22: 6355.
  16. Wells DL. Aromatherapy for travel-induced excitement in dogs. J Am Vet Med Assoc 2006; 229: 964-967. https://doi.org/10.2460/javma.229.6.964
  17. Wolfe MS. Selective amyloid-beta lowering agents. BMC Neurosci 2008; 9(Suppl 2): S4.